Antibodies for NHL
 

Anti-cd22 RIT:  Fractionated Radioimmunotherapy (RIT) With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study - earthtimes.org

Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. 

The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. Moreover, because epratuzumab is humanized, it is argued that the new RAIT can be administered to patients repeatedly in smaller doses. Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells.

Milestones in the development of Lym-1 therapy. Hybridoma. 1999 Feb;18(1):1-11. Review. PMID: 10211782 - PubMed

Oncolym - Lymphoma Inf Net | LYM-1 - UCDMC | (Experimental) 
"Clinical trial using the anti-lymphoma Lym-1 antibody, radiolabeled with Yttrium-90 (Y-90) are in progress at UCDMC. No hospitalization is needed and Y-90 can deliver high energy radiation to the lymphoma." The Lym-1 antibody attaches to is the HLA-Dr10 protein, a cell surface marker present on over 80% of lymphoma cells. (Phase II/III?)

Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Cancer. 1997 Dec 15;80(12 Suppl):2706-11. PMID: 9406728 - PubMed

Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res. 1995 Jan 15;55(2):318-23. PMID: 7812965 - PubMed

Radiolabeled BLyS protein (LR131) inhibits neoplastic B cell growth in vivo Year: 2002 Abstract No: 39

Fractionated Radioimmunotherapy (RIT) With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study - earthtimes.org

Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. Moreover, because epratuzumab is humanized, it is argued that the new RAIT can be administered to patients repeatedly in smaller doses. Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells.

LymphoCide Y-90  (CD 22 targeted)

Yttrium-90-labeled humanized antibody targeting CD22 receptors in B-cell lymphomas. Primary use is for the treatment of indolent and aggressive NHLs. Every year there are 56,000 newly diagnosed cases and 25,000 deaths. It is currently in Phase I clinical trials. 

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003 Jan;44(1):77-84. PMID: 12515879 - PubMed

CLEARING AGENT COULD ENHANCE RADIOLABELED TREATMENTS: A phase I study evaluating the pharmacokinetics of anti-CD20 fusion protein, synthetic clearing agent and 90yttrium DOTA-biotin. Year: 2002 Abstract No: 9

Pretarget - NeoRx (Experimental) 
Reduces exposure of normal tissue by using a 2-step process.  The first step delivers a non-radioactive antibody with an extra receptor (targeting agent). The radioactive agent is then delivered to the tumor via a small molecule that binds to the   targeting agent but is otherwise innocuously excreted from the body. (Phase II)